CERE - Cerevel Therapeutics GAAP EPS of -$0.66 misses by $0.04
- Cerevel Therapeutics press release ( NASDAQ: CERE ): Q3 GAAP EPS of -$0.66 misses by $0.04 .
- Cash, cash equivalents and marketable securities as of September 30, 2022, were $1,030 million, inclusive of $238.3 million
For further details see:
Cerevel Therapeutics GAAP EPS of -$0.66 misses by $0.04